7/2/2013

The FDA rejected a request from Johnson & Johnson and Bayer AG to expand the use of their blood thinner rivaroxaban, or Xarelto, to prevent stent thrombosis in patients with acute coronary syndrome. The FDA has asked J&J's Jannsen Pharmaceuticals for more information about the drug's use in ACS patients. The agency previously declined a supplemental new drug application for general use of the drug to treat ACS.

Related Summaries